EVIDENCE-BASEDAWAITING CLINICIAN REVIEW

Anti-GBM disease (Goodpasture disease)

Anti-glomerular basement membrane (anti-GBM) disease is a rare autoimmune disorder in which antibodies attack basement membranes in the kidney glomeruli and sometimes the lungs. It can cause rapidly progressive glomerulonephritis and life-threatening pulmonary hemorrhage, so early recognition and treatment are critical.

At a glance

Quick facts

Condition snapshot
Modern name
Anti-GBM disease
Older name
Goodpasture disease
Main organs
Kidneys ± lungs
Key blood test
Anti-GBM antibodies
Key tissue test
Kidney biopsy
Core severe-disease therapy
Plasma exchange + immunosuppression

Names & terminology

How this entity may be named or searched

Anti-GBM disease
Preferred pathophysiologic term for disease caused by circulating antibodies against glomerular basement membrane.
Goodpasture disease
Common historical/clinical synonym for anti-GBM antibody disease.
Goodpasture syndrome
Sometimes used more broadly for pulmonary–renal syndrome; not every pulmonary–renal syndrome is caused by anti-GBM antibodies.
Pulmonary hemorrhage
Bleeding into the lung airspaces can occur with or without obvious coughing of blood.

Structured entity profile

Clinical profile

Condition data
MechanismAutoantibodies against basement membraneAntibodies injure glomerular capillaries and can also affect pulmonary capillaries.
Kidney patternRapidly progressive glomerulonephritisHematuria, proteinuria and quickly rising creatinine are typical.
Lung patternAlveolar hemorrhageCough, breathlessness, anemia or hemoptysis may occur.
Blood testAnti-GBM antibodyUsually a central diagnostic test.
BiopsyLinear IgG along GBMKidney biopsy confirms the characteristic immune pattern and severity.
TreatmentPlasma exchange + immunosuppressionUsed urgently in appropriate active disease to remove antibody and stop production.

Overview

Anti-GBM disease develops when the immune system produces antibodies against a target within basement membranes, particularly in kidney glomeruli and lung alveoli. Kidney injury can progress over days to weeks, producing a rapidly progressive form of glomerulonephritis. Lung involvement can cause diffuse alveolar hemorrhage, which may be clinically obvious or may present mainly as breathlessness and falling hemoglobin. [1] [2]

The condition is rare—NIDDK cites roughly one new case per million people per year. Because outcome depends strongly on kidney function at treatment and the amount of irreversible injury already present, suspected anti-GBM disease is a nephrology emergency rather than a diagnosis to confirm slowly in routine follow-up. [1] [2]

Symptoms and warning signs

Kidney symptoms may include dark or bloody urine, swelling, reduced urine output, nausea, fatigue and high blood pressure, although laboratory abnormalities can precede obvious symptoms. Lung bleeding can cause cough, shortness of breath, chest discomfort or coughing blood; some patients have substantial alveolar bleeding without dramatic hemoptysis. Pallor and fatigue may reflect anemia. [1]

SYMPTOM MATRIX

Think pulmonary–renal syndrome when kidney injury and lung bleeding occur together

Either organ can dominate the initial presentation.

Autoimmune emergency
Kidney clues
  • Blood in urine
  • Protein in urine
  • Rapidly rising creatinine
  • Reduced urine output
  • Edema / high blood pressure
Lung clues
  • Cough
  • Shortness of breath
  • Coughing blood
  • Falling hemoglobin / anemia
  • New diffuse lung infiltrates
Emergency pattern
  • Rapid kidney failure
  • Very low urine output
  • Coughing blood with breathlessness
  • Low oxygen or diffuse pulmonary hemorrhage
  • Severe fluid or electrolyte complications

Suspected anti-GBM disease usually requires urgent nephrology assessment and treatment planning.

Diagnosis

Blood testing for anti-GBM antibodies is central. Urinalysis typically shows hematuria and proteinuria, and blood tests assess creatinine, potassium, hemoglobin and inflammatory or autoimmune alternatives. Because some patients have overlapping ANCA-associated vasculitis, ANCA testing is usually included in a pulmonary–renal syndrome work-up. [1] [2]

Kidney biopsy usually shows crescentic glomerulonephritis and characteristic strong linear staining for IgG along the glomerular basement membrane. The biopsy also estimates how much kidney tissue is still salvageable and helps guide prognosis. Chest imaging and respiratory evaluation assess pulmonary hemorrhage when lung involvement is suspected. [1] [2]

Diagnostic pathway

Confirm antibody disease quickly while staging kidney and lung injury

Testing and treatment may proceed in parallel when the presentation is strongly suggestive.

Pulmonary–renal work-up
1Recognize rapid GN / lung hemorrhageCheck urine, creatinine, hemoglobin, oxygenation and chest findings.
2Send urgent serologyTest anti-GBM antibodies and ANCA; evaluate other immune and infectious causes as appropriate.
3Obtain kidney biopsyConfirm linear IgG pattern and quantify active versus chronic injury when feasible.
4Start disease-directed therapy promptlyDo not delay appropriate specialist treatment when organ-threatening disease is highly likely.
SerologyAnti-GBM antibodycentral diagnostic test
Biopsy hallmarkLinear IgGalong GBM

A small minority of clinically compatible cases may have negative circulating antibody assays, making biopsy particularly important.

Risk factors and possible triggers

Anti-GBM disease is autoimmune and is not contagious. Cigarette smoking and inhaled hydrocarbon exposure have been associated with pulmonary involvement in susceptible people. Respiratory infection or lung injury may also precede disease in some patients, but most cases cannot be reduced to one avoidable trigger. [1]

Overlap with ANCA-associated vasculitis

Some patients are positive for both anti-GBM antibodies and ANCA. These “double-positive” cases can have features of both diseases: acute anti-GBM-type organ injury plus a higher long-term relapse tendency associated with ANCA vasculitis. Identifying overlap affects follow-up even after the acute antibody level becomes negative. [2]

Treatment and management

Standard treatment for active, organ-threatening anti-GBM disease combines plasma exchange, which removes circulating antibodies, with corticosteroids and another immunosuppressive agent to suppress new antibody production. Treatment is generally continued until circulating anti-GBM antibodies are no longer detectable and the acute inflammatory phase is controlled. [1] [2]

Dialysis supports patients with severe kidney failure but does not treat the autoimmune process itself. Kidney recovery is less likely when presentation is very advanced, particularly with dialysis dependence and extensive irreversible crescentic damage, so treatment intensity is individualized. Kidney transplantation is possible after disease is inactive, typically after a sustained period without detectable antibodies. [1] [2]

Treatment & care hub

Remove antibody, stop new antibody production, support failing organs

Anti-GBM disease is one of the classic indications for urgent plasma-exchange-based therapy.

Organ-threatening autoimmunity
Plasma exchangeCore severe-disease therapy

Remove circulating anti-GBM antibody

Repeated exchanges lower antibody burden during active disease.

ImmunosuppressionCore

Stop further antibody production

Corticosteroids plus another immunosuppressive agent are commonly used.

Kidney supportAs needed

Dialysis for severe kidney failure

Dialysis treats complications while the autoimmune process is addressed.

Lung careUrgent when involved

Manage pulmonary hemorrhage

Oxygen, transfusion and critical-care support may be required in severe bleeding.

Recognize→Confirm→Remove antibody→Suppress immunity

Treatment choices depend on kidney salvageability, pulmonary hemorrhage and overall clinical status and should be made by specialist teams.

Prognosis and kidney recovery

Outcome is strongly linked to kidney function and biopsy findings at diagnosis. Patients treated before advanced kidney failure have a better chance of preserving kidney function. Severe presentation with dialysis dependence and extensive crescentic or scarred glomeruli is associated with lower renal recovery, although pulmonary hemorrhage can often respond well to treatment. [1] [2]

Follow-up after the acute episode

Clinicians follow anti-GBM antibody levels, kidney function, urinalysis, blood counts and respiratory status. Classic isolated anti-GBM disease has a relatively low relapse rate once antibodies disappear, while double-positive ANCA cases need longer vasculitis-oriented surveillance. Smoking cessation is especially important in anyone with prior pulmonary hemorrhage. [1] [2]

Rare disease

Anti-GBM disease is reported in roughly 1 person per million each year

Its rarity makes rapid recognition of the pulmonary–renal pattern especially important.

NIDDK — Anti-GBM (Goodpasture’s) Disease ↗
New cases~1 per million/yearNIDDK estimate
Main organskidneys ± lungs
Clinical urgencyhigh
Scope: Reported incidence varies by population and case definition; anti-GBM disease remains rare.

Common questions

Frequently asked questions

Reference content

Sources

  1. NIDDK — Anti-GBM (Goodpasture’s) Disease
  2. KDIGO — KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
  3. National Kidney Foundation — Glomerulonephritis

This article is based on trusted medical sources and is awaiting clinician review. It is not a substitute for personalized medical advice.